PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM

For Preferred Hepatitis C Therapy: Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Holkira Pak (ritonavir/paritaprevir/ombitasvir/dasabuvir), Maviret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Technivie (ritonavir/paritaprevir/ombitasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir/grazoprevir)

Please fax form to: 1-866-840-1509

The most current version of this form supersedes all prior versions. The form may be modified without notice to you and we reserve the right to accept only the current version. Revised September 2017. PREFERRED HEPATITIS-1709

Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy of this form for your records.

Instructions:
1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.
2. The patient/plan member must complete section A.
3. Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
4. Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to 1-866-840-1509, OR mail to TELUS Health, 4141 Dixie Rd. P.O. Box 41154, Mississauga, Ont. L4W 5C9.
5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

A. Information to be Completed by Patient

<table>
<thead>
<tr>
<th>Employee or Insured’s Name</th>
<th>Drug Card Number</th>
</tr>
</thead>
</table>
|                           | __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ _
PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM

For Preferred Hepatitis C Therapy: Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Holkira Pak (ritonavir/paritaprevir/ombitasvir/dasabuvir), Maviret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Technivie (ritonavir/paritaprevir/ombitasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir/grazoprevir)

The form may be modified without notice to you and we reserve the right to accept only the current version. Revised September 2017. PREFERRED HEPATITIS-1709

Date: (DD/MMM/YYYY): __ __ / __ __ / __ __

B. Information to be Completed by Prescribing Physician

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Strength</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Holkira Pak (ritonavir/paritaprevir/ombitasvir/dasabuvir), Maviret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Technivie (ritonavir/paritaprevir/ombitasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir/grazoprevir)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Eligibility Criteria

Genotype 1

Maviret

- Treatment of adults with treatment-naïve genotype 1 chronic hepatitis C (CHC) infection with:
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/168 tablets)\(^\text{1}\)
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

- Treatment of adults with treatment-experienced genotype 1 chronic hepatitis C (CHC) infection with:
  - Fibrosis stage F2 (without cirrhosis) or greater status (Metavir scale or equivalent) who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors (Maximum 8 weeks/168 tablets)\(^\text{II}\)
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

- Treatment of adults with treatment-experienced genotype 1 chronic hepatitis C (CHC) infection with compensated cirrhosis who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors in whom sofosbuvir/velpatasvir/voxilaprevir in contraindicated (Maximum 12 weeks/252 tablets)\(^\text{III}\)

Epclusa\(^\text{IV}\)

- Treatment of adults with genotype 1 chronic hepatitis C (CHC) infection with AND has one of the following:
  - Patients with compensated cirrhosis (Maximum 12 weeks/84 tablets)
  - Patients with decompensated cirrhosis, in combination with ribavirin (Maximum 12 weeks/84 tablets)
  - Non-cirrhotic patients in whom glecaprevir/pibrentasvir is contraindicated AND
    - Fibrosis stage F2 (without cirrhosis) or greater status (Metavir scale or equivalent) who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors (Maximum 12 weeks/84 tablets)

Please fax form to: 1-866-840-1509
Eligibility Criteria

- Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

Harvoni

- Treatment of adults with genotype 1 chronic hepatitis C (CHC) infection
  - Treatment-naïve patients without cirrhosis who have pre-treatment Hepatitis C Virus (HCV) RNA < 6 million IU/mL AND one of the following:
    - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/56 tablets)
    - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/56 tablets)

Zepatier

- Treatment of adults with genotype 1 chronic hepatitis C (CHC) infection
  - Treatment-naïve genotype 1b patients without significant fibrosis or cirrhosis AND one of the following:
    - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/56 tablets)
    - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/56 tablets)

Vosevi

- Treatment of adults with genotype 1 chronic hepatitis C (CHC) infection without decompensated cirrhosis, who have previously been treated with an HCV regimen containing an NS5A inhibitor, or an HCV regimen containing sofosbuvir without an NS5A inhibitor.
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 12 weeks/84 tablets)
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

Non-preferred agents due to the availability of more cost-effective agents:

- Daklinza (combined with Sovaldi or Sunvepra)
- Galexos
- Harvoni (for high viral loads)
- Holkira Pak
- Sovaldi
- Zepatier (with ribavirin)

Genotype 2

Maviret

- Treatment of adults with treatment-naïve genotype 2 chronic hepatitis C (CHC) infection with:
## Eligibility Criteria

- **Epclusa**
  - Treatment of adults with genotype 2 chronic hepatitis C (CHC) infection with one of the following:
    - Patients with compensated cirrhosis (Maximum 12 weeks/84 tablets)
    - Patients with decompensated cirrhosis, in combination with ribavirin (Maximum 12 weeks/84 tablets)
    - Non-cirrhotic patients in whom glecaprevir/pibrentasvir is contraindicated AND
      - Fibrosis stage F2 (without cirrhosis) or greater status (Metavir scale or equivalent) who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors (Maximum 12 weeks/84 tablets), OR
      - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

- **Vosevi**
  - Treatment of adults with genotype 2 chronic hepatitis C (CHC) infection without decompensated cirrhosis, who have previously been treated with an HCV regimen containing an NS5A inhibitor, or an HCV regimen containing sofosbuvir without an NS5A inhibitor.
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/168 tablets), OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

---

## Non-preferred agent due to the availability of more cost-effective agents:

- Daklinza (combined with Sovaldi)
- Sovaldi

---

## Genotype 3

- **Maviret**
  - Treatment of adults with treatment-naïve genotype 3 chronic hepatitis C (CHC) infection with:
    - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/168 tablets), OR
    - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

---

**Epclusa**

The most current version of this form supersedes all prior versions. The form may be modified without notice to you and we reserve the right to accept only the current version. **Revised September 2017. PREFERRED HEPATITIS-1709**
### Eligibility Criteria

- **Vosevi**
  - Treatment of adults with genotype 3 chronic hepatitis C (CHC) infection without decompensated cirrhosis, who have previously been treated with an HCV regimen containing an NS5A inhibitor or an HCV regimen containing sofosbuvir without an NS5A inhibitor.
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis, OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

- **Vosevi**
  - Treatment of adults with genotype 4 chronic hepatitis C (CHC) infection with fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis, OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

### Non-preferred agents due to the availability of more cost-effective agents:

- Daklinza (combined with Sovaldi)
- Sovaldi
- Harvoni
- Zepatier (combined with Sovaldi)

### Genotype 4

- **Maviret**
  - Treatment of adults with treatment-naïve genotype 4 chronic hepatitis C (CHC) infection with
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/168 tablets), OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

- **Technivie**
  - Treatment of adults with genotype 4 chronic hepatitis C virus (CHC) infection with fibrosis stage F2 or greater status without cirrhosis who are either treatment naïve or previously treated with peginterferon (pegIFN) and ribavirin, AND satisfies all of the following (Maximum 12 weeks/168 tablets):
    - Child-Pugh score of A,
    - No previous HCV regimens containing a protease inhibitor (eg. Incivek, Victrelis, Galexos).
    - Non-cirrhotic patients in whom glecaprevir/pibrentasvir is contraindicated, AND
    - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis, OR
    - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post...
Eligibility Criteria

organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months

Epclusa

- Treatment of adults with genotype 4 chronic hepatitis C (CHC) infection with one of the following:
  - Patients with compensated cirrhosis (Maximum 12 weeks/84 tablets)
  - Patients with decompensated cirrhosis, in combination with ribavirin (Maximum 12 weeks/84 tablets)
  - Non-cirrhotic patients in whom glecaprevir/pibrentasvir is contraindicated AND
    - Fibrosis stage F2 (without cirrhosis) or greater status (Metavir scale or equivalent) who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors (Maximum 12 weeks/84 tablets), OR
    - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

Vosevi

- Treatment of adults with genotype 4 chronic hepatitis C (CHC) infection without decompensated cirrhosis, who have previously been treated with an HCV regimen containing an NS5A inhibitor, or an HCV regimen containing sofosbuvir without an NS5A inhibitor.
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 12 weeks/84 tablets), OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

Non-preferred agents due to the availability of more cost-effective agents:

- Daklinza (combined with Sunvepra)
- Galexos
- Sovaldi
- Zepatier

Genotypes 5 and 6

Maviret

- Treatment of adults with treatment-naïve genotype 5 or 6 chronic hepatitis C (CHC) infection with
  - Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 8 weeks/168 tablets), OR
  - Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3,4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 8 weeks/168 tablets)

Epclusa

- Treatment of adults with genotypes 5 and 6 chronic hepatitis C (CHC) infection with one of the following:
  - Patients with compensated cirrhosis (Maximum 12 weeks/84 tablets)
  - Patients with decompensated cirrhosis, in combination with ribavirin (Maximum 12 weeks/84 tablets)
  - Non-cirrhotic patients in whom glecaprevir/pibrentasvir is contraindicated.
PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM
For Preferred Hepatitis C Therapy: Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Holkira Pak (ritonavir/paritaprevir/ombitasvir/dasabuvir), Maviret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Technivie (ritonavir/paritaprevir/ombitasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir/grazoprevir)

Please fax form to: 1-866-840-1509

The most current version of this form supersedes all prior versions. The form may be modified without notice to you and we reserve the right to accept only the current version. Revised September 2017. PREFERRED HEPATITIS-1709

Eligibility Criteria

- Fibrosis stage F2 (without cirrhosis) or greater status (Metavir scale or equivalent) who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not both classes of inhibitors (Maximum 12 weeks/84 tablets), OR
- Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3, 4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

Vosevi

- Treatment of adults with genotypes 5 and 6 chronic hepatitis C (CHC) infection without decompensated cirrhosis, who have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
- Fibrosis stage F2 or greater status (Metavir scale or equivalent) without cirrhosis (Maximum 12 weeks/84 tablets), OR
- Fibrosis stage F1 or F0 and at least one of the following: Co-infection with HIV or Hepatitis B, Co-existent liver disease with diagnostic evidence of fatty liver disease (e.g. non-alcoholic steatohepatitis), Post organ transplant (liver and/or non-liver transplant), Extra-hepatic manifestations, Chronic Kidney Disease (stage 3, 4 or 5), Diabetes receiving treatment with anti-diabetic drugs, or Woman of childbearing age planning pregnancy within the next 12 months (Maximum 12 weeks/84 tablets)

OR

- None of the above criteria applies.

Additional Information: ____________________________________________________________

Physician Information

<table>
<thead>
<tr>
<th>Physician’s Name</th>
<th>License Number</th>
<th>Telephone Number</th>
<th>Fax Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
<th>City</th>
<th>Province</th>
<th>Postal Code</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physician’s Signature</th>
<th>Date: (DD/MMM/YYYY)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>__ __ / ___ ___ / ___ ___</td>
</tr>
</tbody>
</table>

\* Lowest cost agent in this indication
\*\* Product monograph indication and dosing
\*\*\* Product monograph indication and dosing, although not specifically called out in the clinical trials. More costly than Vosevi.
For Preferred Hepatitis C Therapy:  Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Holkira Pak (ritonavir/paritaprevir/ombitasvir/dasabuvir), Maviret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Technivie (ritonavir/paritaprevir/ombitasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Zepatier (elbasvir/grazoprevir)

With the introduction of Maviret, Epclusa remains less expensive in the compensated cirrhotic population due to the cost of a 12 week course of therapy. In the non-cirrhotic population, Maviret is less expensive due to the 8 week treatment course. Epclusa remains the only product indicated in the decompensated population.

Holkira Pak is more expensive now in all situations.

Epclusa is the only option indicated in decompensated cirrhotics. It is less expensive than Maviret in Compensated Cirrhotics. Maviret is cheaper in non-cirrhotics.

Maviret is less expensive than Sovaldi, and is RBV free.

Maviret is lowest cost in the absence of cirrhosis.

Only option in GT2 with decompensated cirrhosis. Cheaper than Maviret in compensated and non-cirrhotics.

Product monograph indication and dosing.

Most cost effective option in the absence of cirrhosis.

Technivie is more expensive than Maviret, but less expensive than Epclusa.

Product monograph indication and dosing.

Sovaldi is no longer cost effective in GT4 with the availability of Maviret.

Zepatier is no longer a cost effective alternative in any situation with the availability of Maviret.

Maviret is the most cost effective option in GT5 and 6.

Only option indicated in decompensated cirrhosis. More cost effective than Maviret in compensated cirrhotics.

Product monograph and dosing.